2.2.0.7 false Spin-off of Industrial Testing Assets to Roka Bioscience, Inc. 0204 - Disclosure - Spin-off of Industrial Testing Assets to Roka Bioscience, Inc. true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Spin-off of Industrial Testing Assets to Roka Bioscience, Inc.[Abstract] 0 gpro_SpinOffOfIndustrialTestingAssetsToRokaBioscienceIncAbstract gpro false na duration Spin Off Of Industrial Testing Assets To Roka Bioscience Inc Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string Spin Off Of Industrial Testing Assets To Roka Bioscience Inc Abstract. false 3 Spin-off of Industrial Testing Assets to Roka Bioscience, Inc. 1 gpro_SpinOffOfIndustrialTestingAssetsToRokaBioscienceIncTextBlock gpro false na duration Spin Off Of Industrial Testing Assets To Roka Bioscience Inc. false false false false false false false false false false false verboselabel false 1 false false false false 0 0   <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Note 4 — Spin-off of Industrial Testing Assets to Roka Bioscience, Inc.</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">     In September 2009, the Company spun-off its industrial testing assets, including the Closed Unit Dose Assay (“CUDA”) system, to Roka Bioscience, Inc. (“Roka”), a newly formed private company focused on developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food safety testing, and other applications. In consideration for the contribution of assets, the Company received shares of preferred stock representing 19.9% of Roka’s capital stock on a fully diluted basis. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">     In addition to the CUDA system, the Company contributed to Roka other industrial assets and the right to use certain of its technologies and related know-how in certain industrial markets. These markets include biopharmaceutical production, water and food safety testing, veterinary testing, environmental testing and bioterrorism testing. Roka also has rights to develop certain infection control tests for use on the CUDA system. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company will receive royalties on any potential Roka product sales, and retains rights to use the CUDA system for clinical diagnostic applications. In addition, the Company is providing contract manufacturing and certain other services to Roka on a transitional basis. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">     The Company determined that Roka is not a variable interest entity and therefore is not included in the Company’s consolidated financial statements. </div> </div>  <!-- Begin Block Tagged Note false false false us-types:textBlockItemType textblock Spin Off Of Industrial Testing Assets To Roka Bioscience Inc. No authoritative reference available. false 1 2 false UnKnown UnKnown UnKnown false true